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Abstract The cDNAs for the two variable domains of the 
antibody 9E10 were cloned from the hybridoma cell line. A 
chimeric 9E10 Fab fragment was produced in E. coli under 
control of the tightly controlled tetracycline promoter. The 
functional Fa b fragment was isolated in a single step via a His6-
tag, which also served for its recognition by a nickel chelate-
alkaline phosphatase conjugate. Thus, the recombinant F.,i, 
fragment permitted the immunochemical detection of the myc 
tag in a sandwich ELISA. The dissociation constant for the 
interaction with the myc tag peptide was determined as 80 ± 5 nM 
by fluorescence titration. In an attempt to produce the smaller 
9E10 F v fragment it was found that its V H domain alone can be 
readily isolated from E. coli as a soluble protein. This unusual 
behaviour may be explained by the 18 amino acid-long CDR-H3 
and could be of value in the design of 'single domain' antibodies. 
© 1997 Federation of European Biochemical Societies. 
Key words: Antibody engineering; E. coli secretion; 
Immunoglobulin; Fab fragment; Myc tag 
or separation and biochemical characterization of a variety 
of proteins that had been genetically fused with the myc tag 
sequence. By means of different experimental techniques the 
monoclonal antibody was used, e.g. for monitoring expression 
of recombinant polypeptides in their foreign hosts and for 
investigating the intracellular targeting of proteins (for some 
topical applications see [6-10]). 
In addition, 9E10 proved to be of considerable value in the 
field of antibody engineering, where the myc tag was utilized 
during the cloning [11,12], bacterial production [13,14], and 
phage display [15,16] of antibody fragments. Thus, in con-
junction with the antibody 9E10 differing recombinant F v , 
scFv , and Fab fragments can be applied for the detection of 
specific antigens in immunochemical assays. 
In order to make 9E10 itself amenable to protein engineer-
ing, we describe here the full length sequences of its variable 
domains and we demonstrate that its bacterially produced F a b 
fragment is directly suited for identifying a myc tag fusion 
protein. 
1. Introduction 2. Materials and methods 
The murine anti-c-m^c antibody 9E10 [1] serves as a wide-
spread immunochemical reagent in cell biology and in protein 
engineering. The IgGl/K monoclonal antibody was originally 
raised against a synthetic peptide immunogen derived from 
the human c-myc proto-oncoprotein [1]. Since then it has 
been utilized in cancer research for detecting and studying 
the distribution of the c-myc oncogene product by immuno-
histochemistry (see e.g. [2,3]). 
Soon after its development it was discovered that the epit-
ope of the antibody, comprising the amino acid sequence 
'Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn', can be ex-
pressed in a different protein context and still confers recog-
nition by the 9E10 immunoglobulin [4]. Thus, the so-called 
myc tag was created, the prototypic example for an increasing 
number of short affinity tags, which have nowadays gained 
considerable popularity as tools for the detection and/or pu-
rification of recombinant proteins [5]. 
In the past years numerous publications appeared where 
9E10 was employed for the immunochemical identification 
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2.1. Cloning procedures 
DNA manipulations were performed according to standard meth-
odology [17]. E. coli K-12 strain JM83 [18] was used for cloning and 
production of the recombinant antibody fragments. Cloning and ex-
pression vectors were from the author's collection (see Table 1). 
2.2. Purification and sequencing of the monoclonal antibody 9E10 
9E10 hybridoma cells were cultured in a 1:1 mixture of Iscove's 
Modified Dulbecco's and Ham's F12 medium containing 10% fetal 
calf serum. After 2 to 3 days 5 to 10 ml of the supernatant was 
applied to a 1 ml column with protein A agarose (Sigma). The column 
was washed with PBS buffer (4 mM KH 2P0 4 , 16 mM Na 2HP0 4 , 115 
mM NaCl) and the antibody was eluted with 0.1 M glycine/HCl pH 
2.8, followed by immediate neutralization with 1 M Tris/HCl pH 8.0 
(80 ul per 1 ml fraction) and dialysis against 100 mM Tris/HCl pH 
8.0. SDS-PAGE revealed that the antibody preparation was pure and 
consisted of a single light and a single heavy chain. The two chains 
were then separated by SDS-PAGE with a borate buffer system and 
electro-transferred to an Immobilon P membrane (Millipore). After 
staining with Coomassie Brilliant Blue R250 the bands were cut out 
and subjected to N-terminal sequencing in an Applied Biosystems 
Procise Sequencer. 
2.3. Amplification of the variable domain genes 
PCR was performed after oligo-dT-primed first strand cDNA syn-
thesis from total RNA of the Mycl-9E10 cell line [1] using Pfu DNA 
polymerase and phosphorothioate primers as previously described 
[19,20]. VH was amplified with the primers VHc3-T, 5'-GAG GTS 
MAR CTG CAG SAG TCW GG, and Vnr2-T, 5'-TGA GGA 
GAC GGT GAC CGT GGT SCC TTG GCC CC. VL was amplified 
with VKcl-T, 5'-GAC ATT GAG CTC ACM CAG WCT CCA KYC 
TCC CTG KCT G, and VKrl-T, 5'-CCG TTT CAG CTC GAG CTT 
GGT SCC WSC WCC GAA CGT. The amplification products were 
purified by agarose gel electrophoresis and cut with the restriction 
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enzymes Pstl and BstEll in the case of VH and Sstl and Xhol in the 
case of VL (cf. underlined recognition sites in the primer sequences). 
The VH and VL genes were separately inserted into the Fab fragment 
expression vector pASK85 (Table 1) that had been cut with the same 
enzymes. Plasmid DNA from several clones was analysed by restric-
tion digest and, for some of them, by double strand dideoxy-sequenc-
ing (2 for VL and 6 for VH) using primers as described [20] and a T7 
sequencing kit (Pharmacia). The variable domain genes from one VL 
clone and one VH clone (with a continuous reading frame; see text) 
were combined into a single plasmid utilizing the Xbal and Ncol 
restriction sites on the vector, yielding pASK85-9E10. 
2.4. Site-directed mutagenesis 
The primers 5'-GTC TCC CCC AGA CTC AAC CAG ATC TAC 
TTC GGC CTG CGC T and 5'-AGA GAT ACA GCC AGG CTA 
GCT GGA GAC TGT GTG AGT ACG ATG TCG GCT T were 
used for correcting the N-terminal coding regions of the cloned VH 
and VL genes, respectively, according to the amino acid sequences that 
had been determined for the hybridoma immunoglobulin (see Re-
sults). During this step the Pstl site at the 5' end of VH was replaced 
by BgKl and the Sstl site at the 5' end of VL was replaced by Nhel (cf. 
Fig. 1). Site-directed mutagenesis was performed with single-stranded 
deoxyuridin-containing pASK85-9E10 plasmid DNA [21] using both 
oligodeoxynucleotides. The plasmid from one positive clone, whose 
proper assembly was confirmed by restriction analysis and by DNA 
sequencing, was designated pASK85-9E10a. The resulting VH and VL 
nucleotide sequences were deposited at the EMBL Database with 
accession codes AJ000488 and AJ000489, respectively. 
2.5. Production of the recombinant antibody fragments 
For the bacterial production of the 9E10 Fab fragment the corrected 
VH and VL genes were transferred from pASK85-9E10a via the re-
striction sites Xbal and BstUll and Ncol and Xhol, respectively, into 
the vector pASK88 (Table 1). The F a b fragment thus encoded on 
pASK88-9E10a carried human constant domains instead of those 
from mouse so that its detection by commercially available, chain-
specific antibodies was easier. Furthermore, the two immunoglobulin 
chains were better separated during SDS-PAGE [22] in this case. A 2 1 
E. coli culture of JM83 transformed with pASK88-9E10a was grown 
in a shaking flask at 22°C to an optical density at 550 nm of 0.5 and 
induced by the addition of 200 ui of a 2 mg/ml solution of anhydro-
tetracycline (ACROS Chimica) in dimethylformamide [23]. After fur-
ther shaking for 2.5 h at 22°C periplasmic cell fractionation and 
IMAC purification of the Fa b fragment was performed as described 
[24]. 
The periplasmic cell fraction containing the D 1.3 scFv fragment [25] 
with a (Gly4Ser)3 linker, which was used as antigen in the ELISA (see 
below), was prepared according to the same procedure. In this case 
the tet promoter vectors pASK98-D1.3 and pASK101-D1.3 were em-
ployed for the synthesis of scFT fragments with the C-terminally fused 
Strep-tag or myc tag, respectively (see Table 1). 
For the bacterial secretion of the 9E10 VH domain the vector 
pASK90 was used (Table 1), which carried the generic cloning cassette 
for Fv fragments from pASK68 [14] inserted between the Xbal and 
Hindlll sites of pASK75 [23]. The VH gene was transferred from 
pASK85-9E10a to pASK90 via the restriction sites Xbal and BstEll, 
yielding pASK90-9E10-VH. Bacterial cell growth and induction was 
performed as above and the soluble VH domain was affinity-purified 
from the periplasmic protein fraction on immobilized engineered 
streptavidin [27] via its C-terminal Strep-tag [26]. Chromatography 
was carried out in the presence of 100 mM Tris/HCl pH 8.0, 150 
mM NaCl, 1 mM EDTA. 2.5 mM desthiobiotin (Sigma) dissolved 
in the same buffer was used for competitive elution [27], 
2.6. ELISA 
ELISA was performed in a 96 well microtitre plate (Becton Dick-
inson) with an incubation time of 45 min at ambient temperature, 
followed by washing three times with PBS/Tween (PBS containing 
0.1% v/v Tween 20), unless otherwise stated. The wells were coated 
with 3 mg/ml lysozyme (Sigma) dissolved in 50 mM NaHCOs pH 9.6 
over night and blocked with 3% w/v BSA, 0.5% v/v Tween 20 in PBS 
for 1 h. After washing with PBS/Tween the wells were incubated in 
the first step with 50 al of the periplasmic protein fraction that con-
tained the D1.3 scFv fragment fused with either the myc tag or the 
Strep-tag. For the second incubation a dilution series of the purified 
9E10 F a b fragment in 50 |xl PBS/Tween was applied. Its concentration 
was determined with a calculated absorption coefficient at 280 nm of 
1.41 mg ml - 1 cm - 1 . PBS/Tween was used as a negative control during 
these two incubations (see legend to Fig. 3). Bound Fa b fragment was 
detected in the third incubation with a nickel chelate-alkaline phos-
phatase conjugate (Qiagen), diluted 1:1000 in PBS/Tween. After fi-
nally washing twice with PBS/Tween and twice with PBS, 100 ul of a 
solution of 0.5 mg/ml -nitrophenylphosphate in 1 M Tris/HCl pH 
8.0, 1 mM ZnSC>4, 5 mM MgCb was added and enzymatic activity 
was measured at 25°C as the change in absorbance at 405 nm per min 
with a SpectraMAX 250 instrument (Molecular Devices). Curve fit-
ting was performed by non-linear least squares regression using an 
equation of the type y = a-xl(b+x) [27]. 
2.7. Peptide synthesis and fluorescence titration 
The myc tag peptide comprising the amino acid sequence Abz-Glu-
Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn-COOH was assembled on 
a PS3 synthesizer (RAININ Instrument Co.) using solid phase Fmoc 
chemistry, except for the 2-aminobenzoyl group (Abz), which was 
coupled as the Boc-protected derivative (Bachem Biochemica). The 
molecular mass of the HPLC-purified peptide was confirmed by ESI 
mass spectrometry. Fluorescence titration of the 9E10 F a b fragment or 
the VH domain was carried out as previously described [27]. Protein 
concentrations were adjusted using calculated extinction coefficients 
[28]. The dissociation constant for the F a b fragment was determined 
from a non-linear least-squares fit of the binding isotherm according 
to bimolecular complex formation after the fluorescence data meas-
ured in the presence of the myc tag peptide had been corrected for the 
small effect that was observed in an independent titration with a 
solution of recrystallized 2-aminobenzamide (MERCK-Schuchardt). 
3. Results 
3.1. Analysis of the variable domain sequences 
The coding sequences for the two variable domains of 9E10 
were amplified after first strand cDNA synthesis from total 
RNA of the cell line and separately cloned in the vector 
pASK85 [23]. Degenerate PCR primers which annealed to 
the partly conserved regions at both ends of the variable do-
Table 1 
Tetp/° expression vectors used in this study 
Plasmid Expression cassette8 Reference 
pASK85 
pASK85-9E10 
pASK85-9E10a 
pASK88 
pASK88-9E10a 
pASK90 
pASK90-9E10-VH 
pASK98-D1.3 
pASK101-D1.3 
OmpA-(VH)-CHlYi-His6;PhoA-(VK)-CK 
OmpA-VH-CHlyi-His6; PhoA-VK-CK 
OmpA-VH-CHlvi-His6; PhoA-VK-CK 
OmpA-(VH)-huCH lyi-His6; PhoA-(VK)-huCK 
OmpA-VH-huCH lTi -His6; PhoA-VK-huCK 
OmpA-(VH)-Strep; PhoA-(VK)-myc 
OmpA-VH-Strep; PhoA-(VK)-myc 
OmpA-VH-sc-VK-Strep 
Omp A-VH -sc- VK -myc 
[23] 
this study 
this study 
[29] 
this study 
A. Skerra, unpuplished 
this study 
A. Skerra, unpuplished 
A. Skerra, unpuplished 
"OmpA and PhoA denote the bacterial signal sequences, whereas Hisg, Strep, and myc represent the different affinity tags used. VH and VK in 
parentheses mean that the corresponding vector just carries the cloning site instead of a variable domain gene. 
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main sequences and Pfu D N A polymerase with proofreading single ' C led to a frameshift within framework region 3 in 
activity were used for this purpose (for details, see Section 2). these clones. 
Only one type of amplification product was found each for V H In order to confirm whether the correct sequences had been 
and for VL (Fig. 1), although in roughly half of the V H se- amplified, the antibody 9E10 was isolated from the culture 
quences a point deletion was observed. The substitution of the supernatant of the hybridoma cell line and its chains were 
nucleotides ' A G ' (position 260/261 in the V H sequence) by a subjected to N-terminal amino acid sequencing. The stretch 
VH: 
Bglll 
1 gaagtagatctggttgagtctggGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGAAACTC 60 
ta a cag 
GluValAsaLeuValGluSerGlyGlvAspLeuValLvsProGlYGlvSerLeuLYsLeu 
61 TCCTGTGCAGCCTCTGGATTCACTTTCAGTCACTATGGCATGTCTTGGGTTCGCCAGACT 120 
SerCysAlaAlaSerGlyPheThrPheSerHisTyrGlyMetSerTrpValArgGlnThr 
==== CDR-Hl === 
121 CCAGACAAGAGGCTGGAGTGGGTCGCAACCATTGGTAGTCGTGGTACTTACACCCACTAT 180 
ProAspLysArgLeuGluTzpValAlaThrlleGlySerArgGlyThrTyrThrHisTyr 
===================== CDR-H2 ==== 
181 CCAGACAGTGTGAAGGGACGATTCACCATCTCCAGAGACAATGACAAGAACGCCCTGTAC 240 
ProAspSerValLysGlyArgPheThrlleSerArgAspAsnAspLysAsnAlaLeuTyr 
241 CTGCAAATGAACAGTCTGAAGTCTGAAGACACAGCCATGTATTACTGTGCAAGAAGAAGT 300 
LeuGlnMetAsnSerLeuLysSerGluAspThrAlaMetTyrTyrCysAlaArgArgSer 
301 GAATTTTATTACTACGGTAATACCTACTATTACTCTGCTATGGACTACTggggccaaggc 360 
GluPheTyrTyrTyrGlyAsnThrTyrTyrTyrSerAlaMetAspTyrTrpGlyGlnGly 
================== CDR-H3 ====================== 
£££ELL 
361 accacggtcaccgtctcctca 381 
ThrThrVa 1 ThrVa 1 SerSer 
VL: 
Nhel 
1 gacatcgtactcacacagtctccagctagcctggctgTATCTCTAGGACAGAGGGCCACC 60 
ag a tctc 
AspIleValLeuThrGlnSerPraAlaSerLexiAlaValSerLeuGlyGlnAraAlaThr 
61 ATCTCCTGCAGAGCCAGCGAAAGTGTTGATAATTATGGCTTTAGTTTTATGAACTGGTTC 120 
IleSerCysArgAlaSerGluSerValAspAsnTyrGlyPheSerPheMetAsnTrpPhe 
================== CDR-Ll =================== 
121 CAACAGAAACCAGGACAGCCACCCAAACTCCTCATcTaTGCTATATCCAACCGAGGATCC 180 
GlnGlnLysProGlyGlnProProLysLeuLeuIleTyrAlalleSerAsnArgGlySer 
====== CDR-L2 ======= 
181 GGGGTCCCTGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCAT 240 
GlyValProAlaArgPheSerGlySerGlySerGlyThrAspPheSerLeuAsnlleHis 
241 CCTGTAGAGGAGGATGATCCTGCAATGTATTTCTGTCAGCAAACTAAGGAGGTTCCGTGG 300 
ProValGluGluAspAspProAlaMetTyrPheCysGlnGlnThrLysGluValProTrp 
========== CDR-L3 ====== 
Xhol 
301 acgttcggagctggcaccaagctcgagatcaaa 333 
ThrPheGlyAlaGlyThrLysLeuGluIleLys 
Fig. 1. Nucleotide and encoded amino acid sequences for the variable domain genes of the antibody 9E10 cloned on pASK88-9E10a. The se-
quences that were part of the degenerate PCR primers at each 5' and 3' end are depicted in lower case letters. The single nucleotides that are 
shown below the consecutive sequences correspond to those sequences which had initially been cloned and include a Pstl (nucleotides 10 to 15 
in VH) and a Ssil (nucleotides 7 to 12 in VL) restriction site, respectively. The singular Bglll and Nhel restriction sites that are shown were in-
troduced during repair via site-directed mutagenesis of the differences compared with the experimentally determined primary structure. The ami-
no acid sequences encoded by the corrected genes (starting with the first residue of each mature antibody chain) are given below with the 
CDRs labelled [33]. The N-terminal regions that were confirmed by amino acid sequencing of the native antibody are underlined. 
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of 18 amino acids that was determined for VH (underlined in 
Fig. 1) corresponded to the cloned sequence, except for Lys 
H3 and Gin H5, whose coding sequences were part of the 
vector. The 20 N-terminal amino acids that were sequenced 
for VL were also in accordance with the amplified cDNA. In 
this case the codons for Glu L3, Thr L7, and Val L9, which 
were either part of the vector or introduced by the PCR pri-
mer, were different. Based on these findings and on the anti-
gen-binding activity of the subsequently produced recombi-
nant Fab fragment (see below) it was concluded that the 
cloned genes indeed represented the variable domains of 9E10. 
3.2. Bacterial production of 9E10 as a functional Fai fragment 
For the production as a recombinant Fab fragment and its 
biochemical characterization the differences between the 
cloned N-terminal coding regions and the experimentally de-
termined amino acid sequences were first corrected by site-
directed mutagenesis (cf. Fig. 1). The two variable domain 
genes were then combined into a generic vector for the bacte-
rial secretion of Fab fragments with human IgGl/K constant 
domains [29], yielding the plasmid pASK88-9E10a. Gene ex-
pression was under control of the tightly regulated and chemi-
cally inducible tet promoter/operator in this case [23]. The two 
encoded polypeptide chains ended each with a Cys residue, 
giving rise to the interchain disulfide bond in the Fab frag-
ment. In addition, the heavy chain had a His6 tag appended 
[24]. 
The chimeric Fab fragment was produced in E. coli at the 
shaker flask scale according to our standard protocol [20,29]. 
The recombinant protein was purified from the periplasmic 
cell fraction in a single step via IMAC with Zn(II) [24], where-
by the 9E10 Fab fragment was eluted as a homogeneous pro-
tein fraction by means of an imidazole concentration gradient. 
SDS-PAGE revealed the presence of both of its chains and the 
correct formation of the interchain disulfide bond (Fig. 2). 
Binding activity for the myc tag was determined with the 
purified 9E10 Fab fragment in an ELISA (Fig. 3). For this 
purpose the scFv fragment derived from the anti-lysozyme 
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Fig. 2. Twelve procent SDS-PAGE of the bacterially produced 9E10 
Fab fragment after IMAC purification from the periplasmic cell frac-
tion. Lanes: 1, molecular size standard (numbers are given in kDa); 
2, purified Fab fragment; 3, as in lane 2, without reduction of the 
disulfide bonds. 
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Fig. 3. Determination of antigen-binding activity for the recombi-
nant 9E10 Fab fragment. (A) Detection of the myc tag in an ELI-
SA. Microtitre plate wells coated with lysozyme were incubated 
with the scFv fragment of the D1.3 antibody carrying either the 
myc tag (filled circles and crosses) or the Strep-tag (open circles). 
Lysozyme and scFv fragment were omitted in a control (open 
squares). A dilution series of the purified 9E10 Fab fragment was 
then added (except for a further control, crosses), followed by detec-
tion with a nickel chelate-alkaline phosphatase conjugate. (B) Fluo-
rescence titration of the purified 9E10 Fab fragment (0.5 uM, circles) 
and the isolated VH domain (1 uM, triangles) with the synthetic 
myc tag peptide. Protein tryptophan and tyrosine fluorescence was 
excited at 280 nm and measured at 345 nm (F„b fragment) or 340 
nm (VH domain). The myc tag was equipped with an Abz group at 
its amino terminus, effecting resonance energy transfer and thus 
strong fluorescence quenching upon complex formation with the 
protein [27]. 
antibody D1.3 [25], which had been equipped with the myc 
tag at its C-terminus, was used as antigen. When this scFv 
fragment was bound to a microtitre plate that had been 
coated with lysozyme a clear concentration-dependent signal 
was obtained upon addition of the 9E10 Fab fragment. No 
signal was detected when the same scFv fragment carrying the 
Strep-tag [13] instead of the myc tag was applied. The precise 
affinity between the 9E10 Fab fragment and the synthetic myc 
tag peptide was determined by fluorescence titration, yielding 
a Kd value of 80 ±5 nM (Fig. 3B). 
3.3. Expression studies with the recombinant 9E10 Fv fragment 
and its Vu domain 
For the production of the smaller Fv fragment of 9E10 a 
vector was constructed based on earlier plasmids [14,23,30] 
that directed secretion of the two variable domains into the 
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Fig. 4. Purification of the 9E10 VH domain carrying the Strep-ta.g 
as a soluble protein from the bacterial periplasmic fraction. (A) Elu-
tion profile of the streptavidin affinity chromatography (see Section 
2). The pure VH domain was obtained in a single peak by competi-
tive elution (arrow). (B) 15% SDS-PAGE of the purified VH do-
main. Lanes: 1, molecular size standard (numbers are given in 
kDa); 2, periplasmic fraction containing the VH domain; 3, flow 
through; 4 to 6, fractions from the peak in (A). 
periplasm of E. coli. In this case the VH domain carried the 
Strep-tag [13] and the VL domain carried a His6-tag at its C-
terminus. When the corresponding recombinant Fv fragment 
was purified via streptavidin affinity chromatography [26,27] 
from the fraction of the soluble periplasmic proteins the VH 
chain remarkably appeared in significant excess (not shown). 
In all cases so far investigated by us Fv fragments had been 
isolated with stoichiometric composition of the two chains. 
This was owing to the gentle elution conditions for Strep-
tag fusion proteins under which the non-covalent domain as-
sociation is retained [13,26]. Although an excess of the VL 
domain, which is known for its tendency to form Bence 
Jones-like dimers [31], can often be detected in the periplasmic 
protein fraction, it gets lost during the affinity chromatogra-
phy as long as it does not carry the same tag. The VH domain, 
on the other hand, aggregates if it is not correctly assembled 
with VL and, therefore, any excess of it normally remains 
associated with the bacterial spheroplasts. 
In order to further investigate the present phenomenon the 
vector pASK90-9E10-VH was constructed, which was devoid 
of the VL gene. As in the case of the Fv fragment the vector 
encoded the VH domain with an N-terminal OmpA signal 
sequence and with the C-terminal Strep-tag. The correspond-
ing periplasmic cell fraction was applied to a streptavidin 
column and bound protein was eluted in a physiological buff-
er that contained desthiobiotin as competitor for the Strep-
tag/streptavidin interaction [27]. Surprisingly, a pronounced 
peak was obtained, which contained the pure immunoglobulin 
chain (Fig. 4). Thus, the 9E10 VH domain can be individually 
produced as a soluble protein in E. coli. However, a specific 
binding activity for the myc tag was not detected in the case of 
this immunoglobulin fragment (Fig. 3B). 
4. Discussion 
The full length cDNA sequences have been elucidated for 
the variable regions of the monoclonal anti-c-myc antibody 
9E10 by means of a polymerase chain reaction with primers 
that hybridize in the FRl and J region, followed by cloning of 
the amplified V genes. Recently, partial sequences were de-
scribed for the same antibody, which had been obtained by 
direct sequencing of one-side PCR products [32]. However, 
although an elaborate strategy had been employed for the 
efficient amplification of the V genes via C region primers, 
the first 42 codons (i.e. including CDR-H1) were missing in 
the published VH sequence and the VL sequence was only 
reported beginning with codon 19. An alignment of those 
sequences (EMBL accession numbers X79789 and X79788, 
respectively) with the cDNA sequences described here re-
vealed moreover 2 differences within the amplified VH region 
and 27 differences within VL. 
From a comparison of the sequences shown in Fig. 1 with 
the Kabat database of immunoglobulin sequences ([33]; the 
6th edition was accessed via the World Wide Web) it was 
concluded that VL belongs to the mouse immunoglobulin kap-
pa chain subgroup III whereas VH belongs to the heavy chain 
subgroup HID. CDR-L1 in the light chain carries a 4 amino 
acid insertion (Ser-Val-Asp-Asn, corresponding to the Kabat 
residues 27A-D), which probably forms a solvent exposed 
loop in the tertiary structure. CDR-H3 consists of 18 amino 
acids and comprises thus one of the most extended murine 
hypervariable loops known so far. 
CDR-H3 of 9E10 is furthermore remarkable as it possesses 
two stretches of three consecutive Tyr residues. Together with 
an additional Tyr residue at its downstream end and one Phe 
residue the fraction of aromatic residues in this hypervariable 
region amounts to 44%. An analysis with the program DNA-
PLOT (accessible through the World Wide Web: http:// 
www.genetik.uni-koeln.de/dnaplot/) revealed that CDR-H3 
most likely originated from the DFL16.1 diversity segment 
(used in reading frame 2) and the JH4 joining region, whereas 
the VH gene segment was derived from the 7183 subfamily. 
Taken together, the two protruding loops formed by CDR-H3 
and CDR-L1 constitute an interesting structural feature, 
which might imply a peculiar binding mechanism of this anti-
body for its pep tide antigen. 
The observation that the isolated VH domain of 9E10 can 
be purified as a soluble entity was unexpected. The notion of 
employing VH domains as 'single domain' antibodies was first 
raised by Ward et al. [11] using the anti-lysozyme antibody 
D1.3 [25] as an example. However, this concept was not much 
further pursued due to experimental difficulties regarding the 
solubility of VH domains (see literature quoted in [34]). Gen-
erally, it was recognized that exposure of the hydrophobic 
38 
surface region in the VH domain which comprises the interface 
in the association with VL normally provokes aggregation in 
the absence of this subunit. 
Recently however, the VH domain of a camel immunoglob-
ulin that is devoid of a light chain was structurally analysed 
[35]. The property of the isolated camel VH domain as a well 
soluble, monomeric protein was attributed to the substitution 
of some hydrophobic surface residues by hydrophilic side 
chains. Furthermore, this immunoglobulin carried an ex-
tremely long CDR-H3 with an additional disulfide bond, 
which partially covered the remainder of the hydrophobic sur-
face area. Large-sized CDR-H3 loops seem to constitute a 
general characteristic of VH domains from camel antibodies 
that lack light chains [36]. 
A similar structural mechanism might therefore account for 
the observed solubility of the 9E10 VH domain, where the 
partially hydrophobic and probably flexible extended CDR-
H3 could accidentally bury some exposed hydrophobic groups 
in the interface region when the VL domain is absent. Struc-
tural analysis will have to be done to support this hypothesis 
but, nevertheless, this finding might stimulate current attempts 
to construct soluble monomeric antibody domains by protein 
engineering [37]. 
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